Knoester P D, Belitser S V, Deckers C L P, Keyser A, Renier W O, Egberts A C G, Hekster Y A
Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands.
J Clin Pharm Ther. 2004 Apr;29(2):131-8. doi: 10.1111/j.1365-2710.2004.00544.x.
Follow-up data on the long-term effectiveness (efficacy and tolerability) of lamotrigine are limited. A useful though crude measure for effectiveness in daily clinical practice is the treatment retention rate determined from drug dispensing data. This study describes the baseline characteristics, the usage patterns and the retention rate of this antiepileptic drug (AED) in a population-based cohort of lamotrigine users in the Netherlands during the first 5 years after its registration in 1995. Data from this cohort are compared with those from the initial randomized clinical trials (RCTs) in patients with refractory epilepsy.
This retrospective cohort study used dispensing data from community pharmacies. Baseline characteristics and usage patterns were evaluated for first time users of lamotrigine in this study. Usage patterns were characterized as continued, add-on or discontinued use during the patient observation time window. Cox regression analysis was used to explore possible relationships between baseline characteristics and specific usage patterns defined. The baseline characteristics and discontinuation rates in this cohort study were compared with RCT data reported in medical literature.
A total of 3598 lamotrigine users were identified. The mean age of the population was 39 years and 54% were female. On average, patients used two other AEDs at the start of lamotrigine therapy and approximately 6% of the patients had no history of prior AED use. The discontinuation rate was 25% after 1 year, and approximately 32% at the end of the 5-year study. Addition of another drug or discontinuation was seen in more than half of the population 3 years after the start of therapy. Concurrent use of valproic acid was associated with a better retention rate. Absence of AED history, use of antidepressants, or use of migraine abortive drugs resulted in an increased likelihood of discontinuing lamotrigine. The population from RCTs differed from the study cohort with respect to age, concurrent use of AEDs and length of follow-up.
Data from RCTs cannot easily be extrapolated to daily clinical practice. In this large, observational study, lamotrigine therapy failed in a considerable number of patients, although the mean retention rate was better than previously reported by others. Population-based linkage of health care records can be used to further clarify the effectiveness of lamotrigine.
拉莫三嗪长期疗效(有效性和耐受性)的随访数据有限。在日常临床实践中,一个虽粗略但有用的有效性衡量指标是根据药物配药数据确定的治疗保留率。本研究描述了1995年在荷兰注册后的前5年中,以人群为基础的拉莫三嗪使用者队列中该抗癫痫药物(AED)的基线特征、使用模式和保留率。将该队列的数据与难治性癫痫患者最初的随机临床试验(RCT)数据进行比较。
这项回顾性队列研究使用了社区药房的配药数据。对本研究中拉莫三嗪的首次使用者的基线特征和使用模式进行了评估。使用模式被描述为在患者观察时间窗口内持续、加用或停用。采用Cox回归分析来探讨基线特征与所定义的特定使用模式之间的可能关系。将该队列研究中的基线特征和停药率与医学文献中报道的RCT数据进行比较。
共识别出3598名拉莫三嗪使用者。人群的平均年龄为39岁,54%为女性。平均而言,患者在开始拉莫三嗪治疗时还使用另外两种抗癫痫药物,约6%的患者既往无抗癫痫药物使用史。1年后停药率为25%,在5年研究结束时约为32%。治疗开始3年后,超过一半的人群出现加用另一种药物或停药情况。同时使用丙戊酸与更好的保留率相关。无抗癫痫药物使用史、使用抗抑郁药或使用偏头痛终止药物会增加停用拉莫三嗪的可能性。RCT中的人群在年龄、同时使用抗癫痫药物情况和随访时间方面与研究队列不同。
RCT数据不易外推至日常临床实践。在这项大型观察性研究中,尽管平均保留率优于其他人先前报道的结果,但拉莫三嗪治疗在相当数量的患者中失败。基于人群的医疗保健记录关联可用于进一步阐明拉莫三嗪的有效性。